SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

30 Jul 2019 07:00

RNS Number : 1051H
James Halstead PLC
30 July 2019
 

 

 

 

30 July 2019

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2019.

 

We are pleased to report that sales for the year were ahead of the comparative year and at a record level. This, we feel, represents a creditable performance in still difficult trading conditions. Flooring installations through the year were wide ranging such as Harrow School, Euro Disney's Hotel New York and Chanel concessions across the globe and the Al Thumama Stadium in Qatar. Our healthcare business continues to make good progress and projects completed included Poissy Hospital in France and the newly built Quillota Hospital in Chile. It is particularly pleasing to report that our UK turnover (representing about 35% of total sales) is ahead of the prior year, by some 7%, in a market that seems to be quite robust despite the well reported high street retailer issues.

 

Across many regions, but especially in Europe competition is ever increasing with new entrants peddling an increasing array of flooring of various degrees of quality and availability. In the German market we have maintained market share but turnover was at a lower level. There are markets with double digit growth and France, South America and Holland are examples. We remain confident that our investment in marketing, sampling, sales representation and training / technical support continue to differentiate us from the pack.

 

Raw material prices are stable and the availability problems of last year have ameliorated and working capital remains robustly managed with our cash generation secure. Our long term focus on delivery of shareholder returns is undiminished.

 

Our profit for the year has grown and will be at a record level, representing modest growth.

 

 

 

 

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

James Halstead plc

Telephone: 0161 767 2500

Mark Halstead, Chief Executive

Gordon Oliver, Finance Director

Hudson Sandler

Telephone: 020 7796 4133

Nick Lyon

Nick Moore

Panmure Gordon (Nominated advisor and broker)

Telephone: 020 7886 2500

Ben Thorne

Dominic Morley

Arden Partners (Broker)

Telephone: 020 7614 5900

Tom Price

Matthew Groves

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTDKLFLKDFFBBE
Date   Source Headline
6th Jun 20124:40 pmRNSSecond Price Monitoring Extn
6th Jun 20124:35 pmRNSPrice Monitoring Extension
1st Jun 20127:00 amRNSTotal Voting Rights
25th May 20122:00 pmRNSDirector/PDMR Shareholding
1st May 20127:00 amRNSTotal Voting Rights
2nd Apr 20123:45 pmRNSDirector/PDMR Shareholding
29th Mar 20127:00 amRNSInterim Results
12th Mar 20124:35 pmRNSPrice Monitoring Extension
1st Mar 20127:00 amRNSTotal Voting Rights
30th Jan 20127:00 amRNSPre-Close Trading Statement
11th Jan 20127:00 amRNSAppointment of Broker
4th Jan 20127:00 amRNSAppointment of non-executive director
3rd Jan 20127:00 amRNSBlocklisting Interim Review
3rd Jan 20127:00 amRNSTotal Voting Rights
6th Dec 20111:00 pmRNSDirector's shareholding
5th Dec 20114:45 pmRNSChange in shareholdings
2nd Dec 20117:00 amRNSAGM Statement
30th Nov 201110:50 amRNSResult of Tender Offer
14th Nov 20117:00 amRNSTender Offer and Trading Update
1st Nov 20117:00 amRNSTotal Voting Rights
28th Oct 20112:00 pmRNSAnnual Financial Report
11th Oct 201111:00 amRNSChange in Director's Holding
3rd Oct 20117:00 amRNSPreliminary Results
6th Sep 20117:00 amRNSNotice of Results
15th Aug 20117:00 amRNSTotal Voting Rights
26th Jul 20117:00 amRNSPre-close Trading Statement
6th Jul 20118:45 amRNSDirector/PDMR Shareholding
1st Jul 20117:00 amRNSBlocklisting Interim Review
3rd May 20117:00 amRNSTotal Voting Rights
15th Apr 20112:40 pmRNSDirector/PDMR Shareholding
1st Apr 20117:00 amRNSTotal Voting Rights
31st Mar 20117:00 amRNSInterim Results
31st Jan 20112:00 pmRNSHolding(s) in Company
31st Jan 20117:00 amRNSPre-close Trading Statement
13th Jan 20113:30 pmRNSIssue of Equity and Total Voting Rights
12th Jan 20119:30 amRNSBonus Issue
4th Jan 20119:45 amRNSTotal Voting Rights
4th Jan 20119:10 amRNSBlocklisting Interim Review
21st Dec 20103:45 pmRNSDirector/PDMR Shareholding
3rd Dec 20107:00 amRNSAnnual General Meeting
1st Nov 20107:00 amRNSTotal Voting Rights
25th Oct 20109:15 amRNSAnnual Report and Accounts
25th Oct 20109:15 amRNSAnnual Report and Accounts
30th Sep 20107:00 amRNSPreliminary Results
23rd Jul 20107:00 amRNSPre-Close Trading Update
1st Jul 20107:00 amRNSBlocklisting Interim Review
6th Apr 201012:00 pmRNSTotal Voting Rights
31st Mar 20104:17 pmRNSDirector/PDMR Shareholding
31st Mar 20107:00 amRNSInterim Results
1st Mar 20107:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.